Rocket Pharmaceuticals, Inc. RCKT
2.61 USD +0.10 (+3.98%)
At closeNov 5, 2026, 5:14 AM EST
2.66 +0.05 +1.92%
Pre-market · Nov 5, 5:14 AM ET
2.48 Day range 2.66
2.17 52-week range 5.45
- YTD
- -25.64%
- 1 year
- -21.39%
News
benzinga.com This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or raised price targets.
benzinga.com Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4 Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.
benzinga.com Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4 Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.- benzinga.com Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and…
- benzinga.com Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
benzinga.com This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.
benzinga.com This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.- benzinga.com Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
benzinga.com Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.
benzinga.com Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited…
benzinga.com Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15 Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.- benzinga.com Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over…
benzinga.com Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.
benzinga.com Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observedRocket is actively engaging with the FDA to align on the path to pivotal trial…
benzinga.com 9 Health Care Stocks Moving In Wednesday's After-Market Session Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
benzinga.com Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180M The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket's gene therapy for severe leukocyte adhesion deficiency-I…- benzinga.com Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of…
benzinga.com Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at benzinga.com/analyst-stock-ratings
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com FDA Outlines Process To Speed Up Rare Disease Therapy Approvals FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
benzinga.com Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket 
benzinga.com TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
benzinga.com Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Dow Surges Over 600 Points; US Durable Goods Orders Fall in April 
benzinga.com Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
- benzinga.com Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price…
- benzinga.com Moderna, REV Group, Rocket Pharmaceuticals And Other Big Stocks Moving Higher On Wednesday U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Wednesday. Here are some big stocks recording gains in today’s session.
- benzinga.com GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in…
- benzinga.com Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 Upgrades
- benzinga.com Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX…
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 236 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 242 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday During Thursday's morning session, 255 companies made new 52-week highs.